You are viewing: US Gene Editing Market analysis
Part of: Gene Editing Market (Global)

The US Gene Editing Market was valued at $643.3 Million in 2024 and projected to reach to $1026.7 Million by 2029, representing a compound annual growth rate of 9.8%. The US gene editing market is positioned for sustained expansion through 2029, driven by increasing FDA approvals of CRISPR-based and alternative gene editing therapies.

US Gene Editing Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US Gene Editing Market Trends and Insights

  • The US leads global adoption of gene editing technologies, driven by substantial investments in research and development, a strong regulatory framework, and increasing clinical applications across therapeutic areas.
  • The US market benefits from the presence of major biotechnology hubs, advanced healthcare infrastructure, and significant venture capital funding supporting innovation in CRISPR, base editing, and prime editing platforms. In the US, the gene editing market is accelerating due to rising prevalence of genetic disorders, growing approval of gene-edited therapeutics, and expanding applications in oncology and rare diseases.
  • The US regulatory environment, particularly FDA guidance on gene editing therapies, has created a favorable pathway for commercialization.
  • By 2029, the US market is expected to capture a substantial share of global gene editing revenues, reflecting the country's leadership in precision medicine and biotechnology innovation..

Key Market Statistics

  • CAGR (2024-2029) 9.8% CAGR
  • Market Size, 2024 ~USD 643.3 Million
  • Forecast, 2029 ~USD 1026.7 Million
  • Country US

US Gene Editing Market Overview

Market Valuation :

The US gene editing market is valued at $643.3 million in 2024, with projections reaching $1,026.7 million by 2029, representing a robust 9.8% CAGR over the forecast period.

R&D Investment Leadership :

The US dominates global gene editing innovation through substantial government and private sector R&D investments, supported by NIH funding, venture capital, and pharmaceutical company commitments to therapeutic development.

Regulatory Advancement :

The FDA's established regulatory pathways for gene editing therapies, including breakthrough designation programs, accelerate clinical development and market entry for innovative treatments in the US.

Therapeutic Expansion :

US clinical applications span oncology, rare genetic disorders, cardiovascular diseases, and immunotherapy, with multiple candidates in late-stage trials driving near-term commercialization opportunities.

US Gene Editing Market Dynamics

  • Major pharmaceutical and biotech companies are scaling manufacturing capabilities and expanding clinical pipelines, while academic institutions continue advancing foundational research.
  • Healthcare providers are integrating gene editing solutions into treatment protocols, particularly for previously untreatable genetic conditions. Key growth catalysts include rising healthcare spending on precision medicine, growing patient awareness, and strategic partnerships between biotech firms and established pharmaceutical companies.
  • Reimbursement frameworks are evolving to support gene editing therapies, though cost-effectiveness remains a consideration.
  • The US market will likely see consolidation among smaller biotech firms and increased competition from international players seeking market access..

Market Ecosystem

logo-mobile

GENE EDITING MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Collaborates with Beam Therapeutics to develop in vivo base editing therapies targeting rare genetic diseases affecting the liver, muscles, and central nervous system. The programs utilize precision genome editing and lipid nanoparticle-based delivery technologies. Supports the development of targeted genetic medicines, enables precise modification of disease-associated DNA sequences, and advances research into potential treatments for inherited disorders.
company logo
Supports genome editing research through its Somatic Cell Genome Editing (SCGE) program, focusing on CRISPR-based technologies, targeted delivery systems, genome editing efficiency, and safety evaluation for therapeutic applications. Accelerates the development of genome editing tools, improves editing specificity and delivery efficiency, supports off-target analysis, and advances research into potential gene editing therapies for genetic diseases.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Key Takeaways

  • The US gene editing market is valued at $643.3 million in 2024 and will reach $1,026.7 million by 2029, representing a 9.8% CAGR.
  • The US dominates global gene editing adoption through advanced regulatory frameworks, substantial R&D investment, and a robust biotechnology ecosystem.
  • Clinical approvals and expanding therapeutic applications in rare diseases and oncology are driving US market growth through 2029.
  • The US market leadership is supported by venture capital funding, academic research institutions, and FDA-enabled pathways for gene-edited therapeutics.

Gene Editing Market Report Scope

Report Metric Details
Base Year 2024
Fastest Growing Segment CROS & CDMOS (End User)
Forecast Period 2024–2029
Growth Rate CAGR of 10.2% from 2024 to 2029
Largest Segment PRODUCTS (Offering)
Market Size Base Year (Billions) ~USD 4.67 (2024)
Revenue Forecast (Billions) ~USD 7.59 (2029)
Segments Covered Offering, Type, Technique, Technology, Application, End User

US Gene Editing Market Report Segmentation

6 segment dimensions are covered across the global market.

By Offering

  • Products
  • Services

By Type

  • Cell Line Development & Engineering
  • Gene Editing Kits
  • Gene Editing Libraries
  • Gene Editing Reagents
  • Grna Synthesis & Vector Construction
  • Library Construction & Screening
  • Other Services
  • Reagents & Consumables
  • Software & Systems

By Technique

  • Gene Silencing
  • Knock-In
  • Knock-Out
  • Other Techniques

By Technology

  • Antisense
  • Base Editing
  • Crispr
  • Other Technologies
  • Rnai
  • Talens
  • Zfns

By Application

  • Cell Line Engineering
  • Drug Discovery & Development
  • Genome Editing
  • Other Applications

By End User

  • Academic & Research Institutes
  • Cros & Cdmos
  • Other End Users
  • Pharmaceutical & Biotechnology Companies

US: GENE EDITING SERVICES MARKET, BY END USER, 2022–2029

Segment20222023202420252026202720282029CAGR (%)
ACADEMIC & RESEARCH INSTITUTES199.4186201.6221.6244.1268.7296326.910.2
CROS & CDMOS43.742.948.856.264.674.18597.414.8
OTHER END USERS106.697.2102.9110.4118.6127.4136.8147.27.4
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES290.5269.4290316.7346.5379414.9455.19.4
TOTAL640.3595.5643.3704.9773.9849.1932.71026.79.8

US: GENE EDITING PRODUCTS MARKET, BY END USER, 2022–2029

Segment20222023202420252026202720282029CAGR (%)
ACADEMIC & RESEARCH INSTITUTES421.7395.8402.8435.2471.1509.8552.4599.88.3
CROS & CDMOS197.2187.7193.5211.8232.2254.4279306.69.6
OTHER END USERS168152.5149.9156.4163.4170.4177.7185.64.4
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES565.1527532.8572615.3661.6712.3768.57.6
TOTAL1351.91262.912791375.414821596.31721.41860.67.8

Target Audience

  • Pharmaceutical & Biotech Executives : Strategic leaders need US market data to guide R&D investment allocation, clinical trial planning, and go-to-market strategies for gene editing therapies targeting American patients and healthcare systems.
  • Investment & Venture Capital Firms : Investors require detailed US market forecasts, competitive landscapes, and funding trends to identify high-potential gene editing startups and biotech companies for portfolio allocation and exit planning.
  • Healthcare Providers & Hospital Systems : Hospital administrators and clinical leaders need market insights to evaluate gene editing therapy adoption, budget planning, and integration into treatment protocols for US patient populations.
  • Regulatory & Policy Advisors : Regulatory consultants and policy makers require US-specific market data to inform FDA guidance development, reimbursement frameworks, and healthcare policy decisions affecting gene editing accessibility.
  • Market Research & Consulting Firms : Research professionals need comprehensive US market data to support client advisory services, competitive benchmarking, and strategic recommendations for healthcare and life sciences organizations.

Key Companies in the US Gene Editing Market

CompanyHQOwnershipStrongest segments
EPPENDORF AGGermanyPrivate CompanyLiquid handling (pipettes, dispensers, automated systems),Separation & instrumentation (centrifuges, PCR cyclers, ULT freezers),Consumables (tubes, tips, plates, single-use bioreactors),
ILLUMINA INCUnited StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables,
CALYXTUnited StatesPublic CompanyRTDS / Trait Machine platform services,Licensed gene-edited traits (royalties and access fees),Collaborative R&D and proof-of-concept projects,
MAXCYTE, INCUnited StatesPublic CompanyExPERT GTx and VLx (therapeutic-scale instruments),ExPERT STx and ATx (discovery and development instruments),Disposable processing assemblies and consumables,
BECKMAN COULTERUnited StatesPrivate CompanyClinical diagnostics analyzers and reagents (chemistry, immunoassay, hematology, urinalysis, hemostasis, clinical flow cytometry),Research and discovery systems (flow cytometry, centrifugation, liquid handling, genomics and single-cell tools),Industrial and particle characterization instruments,
TAKEDA PHARMACEUTICAL COMPANYJapanPublic CompanyGastroenterology (Entyvio, Takecab/Vocinti, EOHILIA),Rare Diseases & Plasma-Derived Therapies (Takhzyro, Advate, ADZYNMA, Gammagard, Hyqvia, Cuvitru, Flexbumin),Oncology (Adcetris, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, Leuplin/Enantone),
DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and single-use solutions),Life Sciences (tools, genomics, and imaging),Diagnostics (clinical instruments and consumables),
REVVITY, INC.United StatesPublic CompanyDiagnostics assays and instruments (prenatal, neonatal, infectious disease, autoimmunity),Life science reagents and consumables (immunology, cell biology, genomics),Instruments, imaging, and detection platforms,
THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
MERCK KGAAGermanyPublic CompanyLife Science (reagents, consumables, bioprocessing, CDMO/testing services),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, specialty gases, equipment),
GENSCRIPTHong KongPublic CompanyLife Science Services and Products,Biologics Development Services,Industrial Synthetic Biology Products,
AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
LONZASwitzerlandPublic CompanyIntegrated Biologics,Advanced Synthesis (small molecules, ADCs, HPAPIs),Specialized Modalities (cell & gene, microbial, bioscience, mRNA),
SANGAMO THERAPEUTICSUnited StatesPublic CompanyHemophilia A gene therapy collaborations (SB-525 / giroctocogene fitelparvovec),Fabry and other AAV gene therapy programs (ST-920 and related),Genetically modified cell therapy (TX200, kidney transplant),
PRECISION BIOSCIENCESUnited StatesPublic CompanyARCUS platform collaborations and licensing,In vivo HBV and liver disease programs (PBGENE-HBV, iECURE-OTC),Neuromuscular and mitochondrial programs (PBGENE-DMD, PBGENE-3243),
CELLECTIS S.A.FrancePublic CompanyAllogeneic CAR-T for hematologic malignancies (BALLI-01, NatHaLi-01, ALPHA3),Gene therapy and non-hematologic oncology (TRAVERSE, Melanoma, other gene-editing programs),Platform technologies, collaborations, and other R&D-related revenue,
REGENERON PHARMACEUTICALS, INC.United StatesPublic CompanyEYLEA franchise (incl. 8 mg),Dupixent (atopic dermatitis, asthma, other type 2 diseases),Oncology (Libtayo and emerging bispecifics),
TAKARA BIO INC.JapanPrivate CompanyGenetic and cellular research reagents,Instruments (PCR and cellular analysis devices),In vitro diagnostics (COVID-19 and related),

EPPENDORF AG

Eppendorf AG is a German private company founded in 1945 that employs 4,358 people. The company specializes in laboratory equipment and life sciences solutions.

ILLUMINA INC

Illumina Inc. is a publicly traded U.S. company founded in 1998 with 8,625 employees. It is a leading provider of DNA sequencing and genetic analysis technologies.

CALYXT

Calyxt is a publicly traded U.S. company founded in 2010 with 118 employees. The company focuses on plant biotechnology and gene-edited crop development.

MAXCYTE, INC

MaxCyte, Inc. is a publicly traded U.S. company founded in 1998 with 91 employees. It develops cell engineering technologies for therapeutic applications.

BECKMAN COULTER

Beckman Coulter is a private U.S. company founded in 1935 with 11,900 employees. It manufactures laboratory instruments and diagnostic equipment for life sciences research.

TAKEDA PHARMACEUTICAL COMPANY

Takeda Pharmaceutical Company is a publicly traded Japanese pharmaceutical company founded in 1781 with 47,029 employees. It is one of the world's largest pharmaceutical manufacturers.

DANAHER CORPORATION

Danaher Corporation is a publicly traded U.S. company founded in 1969 with 59,000 employees. It operates a diversified portfolio of businesses in diagnostics, life sciences, and environmental solutions.

REVVITY, INC.

Revvity, Inc. is a publicly traded U.S. company founded in 1937 with 11,000 employees. It provides analytical technologies and solutions for life sciences and diagnostics.

THERMO FISHER SCIENTIFIC INC.

Thermo Fisher Scientific Inc. is a publicly traded U.S. company founded in 1956 with 125,000 employees. It is a global leader in serving science with laboratory equipment, reagents, and analytical instruments.

MERCK KGAA

Merck KGaA is a publicly traded German company founded in 1668 with 59,077 employees. It operates in pharmaceuticals, life sciences, and performance materials sectors.

GENSCRIPT

GenScript is a publicly traded company based in Hong Kong, founded in 2002 with 6,165 employees. It provides biotechnology services including gene synthesis, protein production, and antibody development.

AGILENT TECHNOLOGIES, INC.

Agilent Technologies, Inc. is a publicly traded U.S. company founded in 1999 with 18,000 employees. It manufactures analytical instruments and laboratory equipment for life sciences and diagnostics.

LONZA

Lonza is a publicly traded Swiss company founded in 1897 with 20,000 employees. It provides contract manufacturing and life sciences solutions for pharmaceuticals and biotechnology.

SANGAMO THERAPEUTICS

Sangamo Therapeutics is a publicly traded U.S. company founded in 1995 with 142 employees. It develops gene therapy and cell therapy treatments using zinc finger protein technology.

PRECISION BIOSCIENCES

Precision Biosciences is a publicly traded U.S. company founded in 2006 with 66 employees. It develops gene-editing therapies using its proprietary genome editing platform.

CELLECTIS S.A.

Cellectis S.A. is a publicly traded French company founded in 1999 with 227 employees. It develops immunotherapy treatments using gene-edited cell technologies.

REGENERON PHARMACEUTICALS, INC.

Regeneron Pharmaceuticals, Inc. is a publicly traded U.S. company founded in 1988 with 15,343 employees. It discovers, develops, and commercializes medicines for serious medical conditions.

TAKARA BIO INC.

Takara Bio Inc. is a private Japanese company founded in 2002 with 1,779 employees. It develops and manufactures biotechnology products and services for life sciences research.

Reasons to Buy this Report

  • Market Size & Growth Validation : Obtain precise US market valuation ($643.3M in 2024) and verified forecast data ($1,026.7M by 2029) to support investment decisions, business planning, and competitive positioning in the American gene editing sector.
  • Regulatory & Clinical Landscape : Understand FDA approval pathways, breakthrough designation programs, and clinical trial pipelines specific to the US market to identify commercialization timelines and market entry opportunities for gene editing therapies.
  • Competitive Intelligence : Analyze leading US biotech and pharmaceutical players, their R&D investments, partnership strategies, and market share to benchmark performance and identify acquisition or collaboration targets.
  • Investment & Funding Trends : Access data on venture capital flows, government R&D funding, and private equity activity in the US gene editing sector to identify emerging companies and investment hotspots.
  • Therapeutic Application Insights : Evaluate US clinical applications across oncology, rare diseases, and immunotherapy to prioritize development focus areas and understand unmet medical needs driving market demand.

Frequently asked questions

What is the current size of the US gene editing market?

The US gene editing market is valued at $643.3 million in 2024 and is projected to grow to $1,026.7 million by 2029.

What is the growth rate of the US gene editing market?

The US gene editing market is growing at a compound annual growth rate (CAGR) of 9.8% from 2024 to 2029.

What factors are driving growth in the US gene editing market?

Key drivers in the US include rising prevalence of genetic disorders, FDA approvals of gene-edited therapeutics, expanding clinical applications, and significant venture capital investment in biotechnology innovation.

Which gene editing technologies are most prevalent in the US market?

The US market is dominated by CRISPR-Cas9 technology, with growing adoption of base editing and prime editing platforms for therapeutic applications.

How does the US gene editing market compare to global trends?

The US leads global gene editing adoption with a 9.8% CAGR, slightly below the global average of 10.2%, reflecting the US market's maturity and established regulatory pathways.

RESEARCH METHODOLOGY

This study involved four major activities in estimating the current size of the gene editing market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used primarily to identify and gather information for this extensive, technical, market-oriented, and commercial study. The secondary sources referred to for this research study include publications from government sources, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceutical Research and Manufacturers of America (PhRMA), Global Cancer Observatory (GLOBOCAN), Centers for Disease Control and Prevention (CDC), and European Federation of Biotechnology. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global gene editing market, and the findings were validated through primary research.

Primary Research

In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Gene Editing Market 
 Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global gene editing market size was estimated using multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various market subsegments. The research methodology used to estimate the market size includes the following:

Gene Editing Market Top Down and Bottom Up Approach

Data Triangulation

After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.

Market Definition

Gene editing refers to technologies used to modify, insert, delete, or regulate specific DNA sequences in cells and organisms. These technologies enable targeted genetic modifications through approaches such as CRISPR-Cas, transcription activator-like effector nucleases (TALENs), zinc finger nucleases (ZFNs), base editing, and other genome engineering techniques. The gene editing market includes products such as reagents & consumables and software & systems, as well as specialized services such as cell line development & characterization, gRNA synthesis & vector construction, and library construction & screening. These products and services are widely used in cell line engineering, genome editing, drug discovery and development, and genetic research. They also support applications in biotechnology, biopharmaceutical production, and therapeutic development. Rising investment in genetic research, advances in genome-editing technologies, and the growing adoption of precision medicine are driving demand for gene editing products and services across pharmaceutical, biotechnology, and academic research institutions.

Key Stakeholders

  • Academic Research Institutes
  • Raw Materials Manufacturers & Distributors
  • Contract Research Organizations (CROs)
  • Service Providers
  • Market Research and Consulting Firms
  • Pharmaceutical & Biotechnology Companies
  • Regulatory Agencies
  • Venture Capitalists
  • Government Organizations
  • Private Research Firms
  • Contract Development and Manufacturing Organizations (CDMOs)

Report Objectives

  • To define, describe, and forecast the gene editing market by product & service, technology, application, end user, and region
  • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall gene editing market
  • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil and the Rest of Latin America), the Middle East (GCC Countries and the Rest of the Middle East), and Africa
  • To profile the key players and analyze their market shares and core competencies
  • To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
  • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

Available customizations:

Based on the market data, MarketsandMarkets offers customizations to meet the company’s specific needs. The following customization options are available for the report:

Geographical Analysis

  • Further breakdown of the market in the Rest of Europe, by country
  • Further breakdown of the market in the Rest of Asia Pacific, by country

Company Information

  • Detailed analysis and profiling of additional market players (up to five)

Segment Analysis

  • Cross-segment analysis

 

Get the Full Gene Editing Market Report

Full forecast, segment splits, and company analysis for all Gene Editing Market.

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
DMCA.com Protection Status